Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV
NCT06233331Phase 1Not yet recruiting
- Sponsor
- Emory University
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate) in Squamous Intraepithelial Lesion (SIL) and anal intraepithelial neoplasia (AIN) (3 arms), sponsored by Emory University. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate)
03
Conditions
Squamous Intraepithelial Lesion (SIL)anal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on NCT06233331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233331.